The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.
 
Katy Beckermann
Research Funding - Bristol-Myers Squibb
 
Christine M. Bestvina
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Pfizer
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - EMD Serono
 
Jennifer G. Whisenant
Research Funding - EMD Serono (Inst)
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on a patent licensed to Anasys Instruments.
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Lynne D Berry
No Relationships to Disclose
 
Yu Shyr
Consulting or Advisory Role - Aduro Biotech; GlaxoSmithKline; Janssen Research & Development; Novartis; Pfizer; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Royalty for TNBCType for Insight Genetics. TNBCType is a web-based subtyping tool TNBCtype for candidate TNBC samples using our gene expression meta data and classification method.
 
Chris Liang
Employment - Tyrogenex; Xcovery
Leadership - Tyrogenex; Xcovery
Stock and Other Ownership Interests - Tyrogenex; Xcovery
 
Giovanni Selvaggi
Employment - Xcovery
Stock and Other Ownership Interests - Xcovery
 
Heather A. Wakelee
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda
 
Leora Horn
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; EMD Serono; Genentech; Incyte; Merck; Pfizer; Tesaro; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Xcovery